As atopic dermatitis treatment advances from traditional immunosuppressants and topical steroids to high-cost biologics and oral JAK inhibitors, payers are recalibrating how—and when—patients gain access to systemic therapy. Our latest Formulary Frontlines analysis compares how Blue Cross Blue Shield, Cigna, and UnitedHealthcare manage coverage across key atopic dermatitis treatment classes, revealing distinct differences in tiering strategy, utilization management, and escalation pathways.